Diagnostics prove defensive for Abbott, as the company jumps the FDA’s gun with its third coronavirus test.
Vascular robotics is growing fast and Corindus is the leader here, but Healthineers will need an aggressive sales plan.
Sanofi needs more than Dupixent for its speciality care division to remain a bright spot.
Novartis is the latest big pharma company to pledge not to increase drug prices. But does this signal a shift in the industry?
With growth stalling at some of the industry's biggest biotechs is it time to take a leaf out of big pharma's M&A playbook?
Philips prioritises artificial intelligence-based technologies as it seeks to grow its Connected Care and Health Informatics unit